Provide a valuable resource to your clients or customers by linking to this resource page. Just place the following link on your website.
Hadlima is an adalimumab-bwwd injection and a biosimilar to Humira. It is a tumor necrosis factor blocker used for several inflammatory conditions. Its labeled uses include certain forms of arthritis, inflammatory bowel disease, plaque psoriasis, hidradenitis suppurativa, and uveitis.
read more about hadlima ...Hadlima blocks tumor necrosis factor, a protein involved in inflammation. Lowering this inflammatory signal helps control symptoms of conditions covered by its label. A biosimilar is highly similar to its reference biologic and has no clinically meaningful differences for its approved uses.
Hadlima is injected under the skin. The dose and schedule depend on the condition, age, and stage of treatment. A patient or caregiver can give injections after receiving appropriate training.
Injection-site reactions and infections can occur. Hadlima carries boxed warnings for serious infections and malignancy. Contact your care team promptly for signs of infection, and seek urgent care for a severe allergic reaction.
Your clinician will test for latent tuberculosis before treatment. Tell the care team about current infections, a history of hepatitis B, and other medicines that affect the immune system. Discuss vaccinations before starting Hadlima, since live vaccines should be avoided during treatment.
Hadlima is an FDA-approved biosimilar to Humira, not the identical branded product. Its label lists the conditions for which Hadlima is approved.
It is injected under the skin. The dosing schedule varies by condition.
Hadlima can increase the risk of serious infections, including tuberculosis. The label directs testing for latent tuberculosis before treatment.
The label says not to start Hadlima during an active infection. Tell your prescriber about any infection symptoms before an injection.
Adalimumab (subcutaneous route) - Side effects & dosage. Mayo Clinic. https://www.mayoclinic.org/drugs-supplements/adalimumab-subcutaneous-route/description/drg-20066817. Date Accessed October 6, 2026.
Adalimumab Injection. MedlinePlus. https://www.medlineplus.gov/druginfo/meds/a603010.html. Date Accessed October 6, 2026.
HADLIMA- adalimumab-bwwd solution. DailyMed (National Library of Medicine). https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c361dd60-c88d-4f3c-b98c-79687bbc3450. Date Accessed October 6, 2026.
HADLIMA? (adalimumab-bwwd) | Official HCP Site. Organon. https://organonpro.com/en-us/product/hadlima/about-hadlima/. Date Accessed October 6, 2026.
Purple Book: Product Details for Hadlima (adalimumab-bwwd). U.S. Food and Drug Administration. https://purplebooksearch.fda.gov/index.cfm?blaNo=761059&event=productdetails. Date Accessed October 6, 2026.